Pfizer – Improving Health Equity in IBD through Disparities Research – RFP

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire within unit

Memorial Deadline: Tuesday 3rd, October 2023

External Deadline: Wednesday 11th, October 2023


Please note: The Memorial Deadline for this competition has been extended by one day to accommodate Thanksgiving holiday.

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Geographic Scope: Global

Clinical Area: Inflammatory Bowel Disease (IBD)

Link to full RFP: Improving Health Equity in IBD through Disparities Research

Application Due Date: October 11, 2023

Specific Area of Interest: The intent of this RFP is to support research initiatives related to IBD such as:

– Precision medicine approach which is the tailoring of medical treatment to the individual patient, encompassing a multitude of data-driven (including multi-omics) approaches to foster appropriate clinical decision-making.  Examples include, but are not limited to, the following:

  • Identifying clinical or laboratory characteristics of patients who have mild disease or remain in long-term remission, and studying whether patients with comorbidities have a different disease course
  • Collecting data on access to care for patients from underserved communities in order to tailor treatments more specifically
  • Meta-analysis or Systematic Literature Review (SLR) to further characterise potential differences underrepresented groups vs. general population in terms of disease course or treatment response

– Research on ways to improve IBD management specifically treat to target approach among underserved groups, such as treat to target approaches

– Studies quantifying the socio-economic burden of IBD in the world stratified by ethnicity, race, socio-economic status, age, health literacy, sexual orientation, comorbitidies, mental and emotional burden of IBD

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Sarthak Pandit, Grant Officer (

Application submission deadline: October 11, 2023
• Anticipated decision notification date: December 10, 2023
• Anticipated project start date: January 10, 2024

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: July 27, 2023